University of Utah
Pharmacy in Salt Lake City, UT
License number
Utah 103501-8913
Issued Date
Jan 12, 1993
Expiration Date
May 31, 2001
Category
Pharmacy
Type
Dispensing Controlled Substance License
Address
Address
Salt Lake City, UT
Personal information
See more information about University of Utah at radaris.comName
Address
Phone
1071 E 100 S #A100, Saint George, UT 84770
250 S 1850 E, Salt Lake City, UT 84112
Hyper E 214 B East Campus, Salt Lake City, UT 84112
270 S 1400 E, Salt Lake City, UT 84112
330 S 1500 E #106, Salt Lake City, UT 84112
Organization information
See more information about University of Utah at bizstanding.comUniversity of Utah
2177 Downington Ave, Salt Lake City, UT 84108
Industry:
Orthopedics
Phone:
(801) 587-7109 (Phone)
University Of Utah
127 S 500 E STE 160, Salt Lake City, UT 84102
Categories:
Science of Mind Churches
Phone:
(801) 587-6701 (Phone)
University of Utah
24 S 1100 E, Salt Lake City, UT 84102
Industry:
Thoracic Surgery
Phone:
(801) 746-4440 (Phone)
University of Utah
44 N Medical Dr, Salt Lake City, UT 84113
Industry:
Pediatric Oncologist, Hospitals, Pediatrician, ...
Phone:
(801) 584-8246 (Phone)
The University of Utah
2400 Lngg Cmmncation, Salt Lake City, UT 84112
Industry:
College/University
Phone:
(801) 581-6888 (Phone)
Branch Manager:
Carol Chadburn (Branch Manager)
University of Utah
350 Middle Oak Ln, Salt Lake City, UT 84108
Industry:
College/University
Medical Doctors:
Kristen Vinik (Principal),Teri Jo Mauch (Medical Doctor),Patrick William Shea (Medical Doctor),...
University of Utah
4677 Citadel St, Salt Lake City, UT 84120
Industry:
Colleges and Universities
Manager:
Travis Johnson (Manager)
SIC:
8221 - Colleges, Universities, and Professional Schools
University of Utah
30 N 1900 1C026 E, Salt Lake City, UT
Industry:
Surgeons, Emergency Medicine
Phone:
(801) 581-2730 (Phone)
University of Utah Inc
1645 Campus Ctr Dr, Salt Lake City, UT 84112
Industry:
Colleges and Universities
Phone:
(801) 581-7676 (Phone)
Attorneys:
Jack Brittain (Director),John Harris (Attorney)
SIC:
8221 - Colleges, Universities, and Professional Schools
Company size:
499
University Of Utah Hospital
50 N Medical Dr, Salt Lake City, UT 84132
Industry:
Anesthesiology, Surgeons, Physical Medicine
Professional information
Homogeneous Multiple Band Gap Devices
US Patent:
2013009, Apr 25, 2013
Filed:
Oct 19, 2012
Appl. No.:
13/656565
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Ye Zhang - Salt Lake City UT, US
Rujie Sun - Salt Lake City UT, US
Ye Zhang - Salt Lake City UT, US
Rujie Sun - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
H01L 31/0352, H01L 33/06
US Classification:
257 28, 257E33005, 257E31037
Abstract:
An electrical device comprising (A) a substrate having a surface and (B) a nanohole superlattice superimposed on a portion of the surface is provided. The nanohole superlattice comprises a plurality of sheets having an array of holes defined therein. The array of holes is characterized by a band gap or band gap range. The plurality of sheets forms a first edge and a second edge. A first lead comprising a first electrically conductive material forms a first junction with the first edge. A second lead comprising a second electrically conductive material forms a second junction with the second edge. The first junction is a Schottky barrier with respect to a carrier. In some instances a metal protective coating covers all or a portion of a surface of the first lead. In some instances, the first lead comprises titanium, the second lead comprises palladium, and the metal protective coating comprises gold.
Electrochemical Flow Cytometry
US Patent:
2013013, May 23, 2013
Filed:
Jan 11, 2013
Appl. No.:
13/739800
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Richard Rabbitt - Salt Lake City UT, US
Richard Rabbitt - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/02
US Classification:
435 29
Abstract:
A method for triggering cellular exocytosis events and measuring quantal release of electroactive chemicals is disclosed. A method can include flowing a cell through a single cell channel having a pair of electrodes oriented to direct current through the cell at a stimulation location along the single cell channel. The pair of electrodes include a working electrode, a counter electrode and an optional reference electrode. The single cell channel has dimensions which provide direct contact of the cell with walls of the single cell channel sufficient to substantially reduce or eliminate shunt paths around the cell at the stimulation location. The cell can be exposed to an electric field at the stimulation location using the pair of electrodes sufficient to trigger exocytosis. Changes in current due to exocytosis processes appear as spikes that can be correlated with a quanta of the electroactive chemicals which are released during exocytosis.
Methods For Assessing Risk For Cardiac Dysrythmia In A Human Subject
US Patent:
2013016, Jun 27, 2013
Filed:
Sep 17, 2012
Appl. No.:
13/621789
Inventors:
University of Utah - Salt Lake City UT, US
University of Utah Research Foundation - Salt Lake City UT, US
University of Utah Research Foundation - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
UNIVERSITY OF UTAH - Salt Lake City UT
UNIVERSITY OF UTAH - Salt Lake City UT
International Classification:
C12Q 1/68
US Classification:
435 611, 435 612, 435 792, 436501
Abstract:
The present invention relates to methods for assessing the risk of a patient for developing a potentially fatal cardiac dysrhythmia and for diagnosing Andersen's Syndrome. A tissue sample from a patient is obtained and the DNA or proteins of the sample isolated. From the DNA and protein isolates the sequence of the KCNJ2 gene or the Kir2.1 polypeptide can be obtained. The KCNJ2 gene or the Kir2.1 can be screened for alteration as compared to the wile-type sequence. An alteration in a copy of the KCNJ2 gene or a Kir2.1 polypeptide indicates that the patient has a high risk for developing a cardiac dysrhythmia and can be diagnosed with Andersen's Syndrome. The invention also related to isolated nucleic acid molecules with one or more alterations as compared to the wild-type sequence.
Methods For Analysis Of Free And Autoantibody-Bound Biomarkers And Associated Compositions, Devices, And Systems
US Patent:
2013018, Jul 18, 2013
Filed:
Nov 14, 2012
Appl. No.:
13/676980
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Alan L. Rockwood - Riverton UT, US
A. Wayne Meikle - Salt Lake City UT, US
Alan L. Rockwood - Riverton UT, US
A. Wayne Meikle - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
G01N 33/53
US Classification:
436501, 422430
Abstract:
The present invention provides methods, compositions, and kits associated with analyzing, enriching, and/or isolating a biomarker or analyte in a biological sample. In one aspect, for example, a method for determining a concentration of a biomarker in a biological sample can include binding any unbound biomarker with an antibody specific for the biomarker to form antibody-bound biomarker, enriching the antibody-bound biomarker and any endogenous autoantibody-bound biomarker to form an enriched fraction, identifying the biomarker in the enriched fraction, and determining the concentration of the biomarker in the biological sample. In one aspect, the concentration of the biomarker is derived from initially unbound biomarker and autoantibody-bound biomarker in the biological sample.
Methods And Compositions Related To Dlk-1 And The P38 Mapk Pathway In Nerve Regeneration
US Patent:
2013019, Jul 25, 2013
Filed:
Mar 10, 2013
Appl. No.:
13/792181
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Erik Jorgensen - Salt Lake City UT, US
Paola Nix - Salt Lake City UT, US
Marc Hammarlund - Hamden CT, US
Erik Jorgensen - Salt Lake City UT, US
Paola Nix - Salt Lake City UT, US
Marc Hammarlund - Hamden CT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
A61K 31/713, A61K 31/7088
US Classification:
514 44 A, 514 44 R, 536 232, 536 245, 506 10
Abstract:
Disclosed are compositions and methods for treating neurodegenerative disease.
Vision Correction System
US Patent:
2013020, Aug 8, 2013
Filed:
Mar 14, 2013
Appl. No.:
13/828308
Inventors:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT, US
Randall J. Olson - Salt Lake City UT, US
Randall J. Olson - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61F 2/16
US Classification:
623 634
Abstract:
A vision correction system comprising an intraocular lens having a lens body and one or more haptics is provided. The lens body may be configured to be positioned posteriorly to an iris of an eye and may have a convex anterior surface, a concave posterior surface, and a circumferential edge having a rounded anterior portion and a rounded posterior portion. Haptics may extend at an anterior angle from the lens body and be configured to contact the ciliary sulcus of an eye. The haptics and/or hydrophobic forces between this lens body and a second intraocular lens may secure the lens body in the eye in a relatively fixed position and prevent rotation of the lens over time.
Multiple Myeloma Prognosis And Treatment
US Patent:
2013010, May 2, 2013
Filed:
Dec 17, 2012
Appl. No.:
13/717264
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Fenghuang ZHAN - Salt Lake City UT, US
Guido TRICOT - Salt Lake City UT, US
Fenghuang ZHAN - Salt Lake City UT, US
Guido TRICOT - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C12Q 1/68, G01N 33/68
US Classification:
435 611, 435 723, 435 614, 435 612
Abstract:
Disclosed herein are diagnostic and prognostic methods for determining the overall survival, and therapeutic regimes, for multiple myeloma patients. The methods involve the detection of PTHR1 gene expression alone or in combination with other clinical factors. The tests are suitable for diagnosing and monitoring treatment of patients having or suspected of having multiple myeloma. The disclosure also relates to proteasome inhibitors and other activators of PTHR1, for the treatment of multiple myeloma.
Pressure Sensitive Microparticles For Measuring Characteristics Of Fluid Flow
US Patent:
2013012, May 16, 2013
Filed:
Dec 21, 2012
Appl. No.:
13/725360
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Carlos H. Mastrangelo - Salt Lake City UT, US
Carlos H. Mastrangelo - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
G01F 1/74, G01N 21/55, C23C 16/01
US Classification:
428402, 216 56, 356442, 2524081
Abstract:
Microparticles () and systems and methods for measuring characteristics of fluid flow using the microparticles are described. The microparticle () can include at least one flexible wall () which can deflect when an outer pressure on an outer side of the wall is different than an inner pressure on an inner side of the wall. The microparticle () can also include a void () enclosed by the at least one wall () and can change shape as the wall () deflects.
Brain Phosphorus Spectroscopy In Bipolar Disorder
US Patent:
2013012, May 16, 2013
Filed:
Oct 16, 2012
Appl. No.:
13/653311
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Douglas G. KONDO - Salt Lake City UT, US
Douglas G. KONDO - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61B 5/055
US Classification:
600410, 514789
Abstract:
Described herein are systems and methods of identifying bipolar disorder in a person. One such method includes acquiring P spectroscopic imaging data from a region of interest in a brain of the person and subsequently analyzing the P spectroscopic imaging data to obtain a signal intensity and a concentration for one or more phosphorus metabolites. A reduced concentration the one or more phosphorus metabolites, such as inorganic phosphate, in the brain can indicate bipolar disorder in the person. Frontal lobe inorganic phosphate concentration in medication-free adolescents can indicate bipolar depression.
Polymeric Compositions And Methods Of Making And Using Thereof
US Patent:
2013012, May 23, 2013
Filed:
Jan 16, 2013
Appl. No.:
13/742877
Inventors:
University of Utah Research Foundation - Salt Lake City UT, US
Meredith C. Roberts - Salt Lake City UT, US
Patrick F. Kiser - Salt Lake City UT, US
Julie I. Jay - Salt Lake City UT, US
Meredith C. Roberts - Salt Lake City UT, US
Patrick F. Kiser - Salt Lake City UT, US
Julie I. Jay - Salt Lake City UT, US
Assignee:
University of Utah Research Foundation - Salt Lake City UT
International Classification:
C08F 30/06, A61K 47/32
US Classification:
424400, 526239, 5147724, 4241301
Abstract:
Described herein are polymeric compositions that comprise at least one polymer residue and at least one crosslinking moiety, wherein the polymer residue is crosslinked by the crosslinking moiety and wherein the crosslinking moiety is formed from a reaction between a boronic acid moiety and a hydroxamic acid moiety. Also, described are methods of making and using such polymeric compositions.